Sarepta Therapeutics (NASDAQ:SRPT) Posts Earnings Results, Beats Estimates By $0.06 EPS

Sarepta Therapeutics (NASDAQ:SRPT) posted its earnings results on Thursday. The biotechnology company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.06, FiscalAI reports. The firm had revenue of $381.35 million during the quarter, compared to the consensus estimate of $352.20 million. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The firm’s revenue for the quarter was down 4.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.13) EPS.

Here are the key takeaways from Sarepta Therapeutics’ conference call:

• Sarepta raised the low end of its 2026 net product revenue guidance by $50 million to $1.25 billion–$1.3 billion, citing strong PMO sales and stabilization in ELEVIDYS. Q3 product revenue was $324 million, down 13% year over year; ELEVIDYS contributed $83 million and the PMO franchise $240 million.
• ELEVIDYS enrollment-form activity was in line with Q2, which management described as a new baseline; the company expects Q4 ELEVIDYS revenue to be roughly in line with Q3. Executives said long-term data and results in patients ages 8–12 are supporting physician and family discussions, but offered no timing for renewed growth.
• Sarepta reported $23 million in Q3 non-GAAP operating profit and nearly $1 billion in cash and investments; management said its base business generated nearly $300 million of cash year to date after adjusting for Arrowhead collaboration payments. The company also narrowed its full-year non-GAAP R&D and SG&A expense guidance to $800 million–$825 million.
• Q3 product-revenue gross margin was 59%, including a $52 million take-or-pay charge for unmanufactured ELEVIDYS inventory that reduced the quarter’s margin by about 19 percentage points. Sarepta also said it expects competition for its exon 51 therapy in early 2027, though it does not expect widespread switching of stable patients initially.
• Data from the DM1 and FSHD multiple-ascending-dose studies are expected in the coming weeks and are intended to guide dose selection and pivotal-trial plans; those programs have not yet demonstrated clinical benefit in these studies. Sarepta will not resume the ENVISION trial, citing practical barriers, and is relying on ENDEAVOR Cohort 8 data to inform discussions with the FDA about ELEVIDYS in non-ambulatory patients.

Sarepta Therapeutics Stock Up 1.4%

Shares of Sarepta Therapeutics stock traded up $0.25 during trading hours on Friday, reaching $17.82. 2,596,194 shares of the company were exchanged, compared to its average volume of 3,007,901. The firm has a market cap of $1.88 billion, a PE ratio of -6.14, a PEG ratio of 0.35 and a beta of 0.45. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.62 and a current ratio of 4.42. Sarepta Therapeutics has a 1 year low of $14.68 and a 1 year high of $24.68. The stock’s fifty day moving average is $19.20 and its 200 day moving average is $18.66.

Sarepta Therapeutics News Summary

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Royal Bank of Canada raised its price target from $17 to $18, while maintaining a “sector perform” rating. Sarepta reported Q3 EPS of $0.13, above the $0.07 consensus cited by MarketBeat, and revenue of $381.35 million versus its $352.20 million estimate. MarketBeat earnings report
• Neutral Sentiment: Baird lowered its price target to $18. The target is close to the $17.82 share price cited in the report, suggesting limited upside at that level. StreetInsider report
• Negative Sentiment: Other earnings coverage said SRPT’s $0.13 EPS missed the Zacks consensus estimate of $0.37. Revenue was down 4.5% year over year, and reports said weaker Elevidys sales weighed on investor sentiment. Published earnings benchmarks differ, so the quarter’s result depends on which estimate is used. Zacks earnings coverage
• Negative Sentiment: A Sarepta-Hansa gene-therapy study has ended, raising questions for investors about the collaboration and its development prospects. The available report summary does not specify the study’s results or implications. TipRanks report

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. HC Wainwright restated a “sell” rating and set a $5.00 price target on shares of Sarepta Therapeutics in a research report on Monday, October 5th. Royal Bank Of Canada boosted their price objective on Sarepta Therapeutics from $17.00 to $18.00 and gave the company a “sector perform” rating in a report on Friday. William Blair raised Sarepta Therapeutics to a “hold” rating in a research note on Wednesday, September 23rd. Weiss Ratings cut Sarepta Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, October 28th. Finally, Wall Street Zen downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Six equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and seven have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average price target of $23.40.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs use RNA-based technologies, gene therapy and other genetic approaches to address the underlying causes of serious neuromuscular disorders.

The company’s primary focus is Duchenne muscular dystrophy (DMD), a progressive genetic disease that causes muscle weakness and loss of function. Sarepta markets Exondys 51 (eteplirsen), Vyondys 53 (golodirsen) and Amondys 45 (casimersen), RNA-based therapies designed to help certain patients produce a shortened but functional form of dystrophin.